REVIEW article
Front. Cardiovasc. Med.
Sec. Cardiovascular Metabolism
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1577952
This article is part of the Research TopicInflammatory Pathways in Cardiometabolic Diseases: Mechanisms, Biomarkers, and Therapeutic InsightsView all 8 articles
A systematic review of the connection between serum uric acid levels and the risk of cardiovascular disease
Provisionally accepted
- 1Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Experiment center of medicine, Shiyan, Hubei 442008, China, Shiyan, Hubei, China
- 2Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Rehabilitation department, Shiyan, Hubei 442008, China, Shiyan, Hubei, China
- 3Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Department of endocrinology and metabolism, Shiyan, Hubei 442008, China, Shiyan, Hubei, China
- 4Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, Hubei 442008, China, Shiyan, Hubei, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Serum uric acid (SUA) has emerged as a significant biomarker for cardiovascular disease (CVD) risk assessment, garnering increasing attention in recent years. As CVD remains a leading cause of global mortality, identifying effective biomarkers for risk stratification is of paramount importance. Current evidence indicates a strong association between elevated SUA levels and increased CVD risk. However, the precise mechanisms and confounding factors underlying this relationship remain unclear. This review examines the link between SUA and CVD, exploring potential biological pathways—including metabolic syndrome, inflammatory responses, and oxidative stress—that may mediate this association. By synthesizing existing literature, this article aims to provide insights for future research and clinical applications, ultimately enhancing the understanding of SUA’s utility in CVD risk evaluation.
Keywords: Serum uric acid, cardiovascular disease, Risk Assessment, metabolic syndrome, Inflammatory Response
Received: 17 Feb 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Wang, Yi, Zhou, Chen, Zhang, Huang and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hui-Min Huang, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Experiment center of medicine, Shiyan, Hubei 442008, China, Shiyan, Hubei, China
Ying Wei, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Experiment center of medicine, Shiyan, Hubei 442008, China, Shiyan, Hubei, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.